Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Mission Wealth Management LP

Mission Wealth Management LP lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,052 shares of the pharmaceutical company’s stock after selling 575 shares during the quarter. Mission Wealth Management LP’s holdings in Vertex Pharmaceuticals were worth $2,437,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VRTX. Grandfield & Dodd LLC grew its position in shares of Vertex Pharmaceuticals by 19.9% in the fourth quarter. Grandfield & Dodd LLC now owns 16,964 shares of the pharmaceutical company’s stock valued at $6,831,000 after purchasing an additional 2,820 shares during the period. Fidelis Capital Partners LLC lifted its stake in Vertex Pharmaceuticals by 1.0% in the 4th quarter. Fidelis Capital Partners LLC now owns 5,520 shares of the pharmaceutical company’s stock valued at $2,223,000 after buying an additional 55 shares in the last quarter. LGT Group Foundation boosted its holdings in Vertex Pharmaceuticals by 5.9% in the 4th quarter. LGT Group Foundation now owns 2,334 shares of the pharmaceutical company’s stock worth $940,000 after buying an additional 129 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth approximately $608,000. Finally, Jones Financial Companies Lllp raised its holdings in shares of Vertex Pharmaceuticals by 75.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company’s stock valued at $994,000 after acquiring an additional 1,062 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $483.31 on Tuesday. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The company has a fifty day simple moving average of $441.95 and a two-hundred day simple moving average of $461.06. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The company has a market cap of $124.11 billion, a price-to-earnings ratio of -219.69, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the transaction, the executive vice president now directly owns 58,539 shares in the company, valued at approximately $27,825,928.26. The trade was a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 1,084 shares of company stock valued at $505,512 over the last quarter. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on VRTX shares. JPMorgan Chase & Co. lowered their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a research note on Monday, December 23rd. Royal Bank of Canada boosted their target price on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a report on Thursday, February 20th. BMO Capital Markets set a $545.00 price target on Vertex Pharmaceuticals in a report on Friday, January 31st. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.